The prevailing grade 1–2 side effect was anemia in 76.7% of the patients, while 61.8% exhibited elevated CRP, 54.2% developed lymphocytopenia, and 48.1% displayed pathologically elevated LDH. The gene discussed is CRP; the disease is lymphopenia.